Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
20 Jun 2024
bởiAudrey Abella
An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.
Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
20 Jun 2024
Physical activity substantially cuts cirrhosis risk in MASLD patients
19 Jun 2024
bởiAudrey Abella
A study presented at DDW 2024 showed that adequate physical activity reduces the risk of cirrhosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
